Quantum Healthcare Limited Completes S\$3 Million Share Placement – Major Expansion of Share Base

Key Highlights

• Quantum Healthcare Limited has completed a substantial placement of 2,727,272,800 new ordinary shares.
• The placement raised an aggregate cash consideration of S\$3,000,000.08 for the company.
• Shares were allotted equally between Ms Chen Liang and Mr Martin Lim Kai Lee, with each receiving 1,363,636,400 shares.
• The company’s total issued and paid-up capital increased from 8,014,501,108 shares to 10,741,773,908 shares.
• The new placement shares are expected to begin trading on the Catalist board of the SGX-ST on 28 November 2025 at 9:00 a.m.
• The placement shares will rank pari passu (equally) with existing shares, except for dividends or distributions declared before their issue date.

Important Information for Shareholders

• This placement represents a significant dilution of approximately 25% to existing shareholders, as the share base expands by over 34%.
• Shareholders should note that dividends, rights, or other distributions declared before the allotment date (26 November 2025) will not be eligible for the new placement shares.
• Potential share price impact: The substantial increase in share base may affect the share price due to dilution. However, the S\$3 million capital infusion could also strengthen the company’s financial position and support growth initiatives.
• The placement participants, Ms Chen Liang and Mr Martin Lim Kai Lee, will each hold approximately 12.7% of the enlarged share capital, which may influence future voting outcomes and corporate direction.
• Further developments related to the Proposed PW Debt Conversion and Proposed Directors’ Fees Capitalisation are pending. These could also impact the company’s capital structure and should be closely monitored by investors.

Additional Details

The placement was conducted in accordance with previously announced terms and received the necessary listing and quotation notice from the SGX-ST. The funds raised are expected to be used for purposes previously outlined by the Board, potentially including business expansion, investments, or working capital.

The company’s sponsor, PrimePartners Corporate Finance Pte. Ltd., has reviewed this announcement, but the Singapore Exchange Securities Trading Limited has not examined or approved its contents.

Further announcements will be made regarding the pending debt conversion and directors’ fees capitalisation, which may also have material effects on the company and its shareholding structure.

Conclusion

This large placement is a major corporate action that could influence Quantum Healthcare Limited’s share price in the short term due to dilution, but it also potentially strengthens the company’s financial resources for future growth. Investors should stay alert for upcoming announcements on debt conversion and directors’ fees capitalisation, as these could further affect the capital structure and valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation. Investors should conduct their own research and consult professional financial advisers before making investment decisions. The Singapore Exchange assumes no responsibility for the contents of this announcement.

View Quantum Health Historical chart here